医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FlexVIA Plasma System from Nordson MARCH Wins Innovation Award for Plasma Surface Treatment of Flexible PCB Materials

2013年05月07日 AM11:40
このエントリーをはてなブックマークに追加


 

CONCORD, Calif.

Nordson MARCH, a Nordson Company (NASDAQ: NDSN), a global leader in plasma processing technology, received the EM Asia-China Award for its FlexVIA Plasma System, a completely self-contained vacuum plasma system designed for maximum efficiency and cost-effective etch, desmear, and surface activation treatment of flexible printed circuit boards (PCBs). The award, presented by EM Asia-China magazine on 23 April 2013, was determined by judging criteria that included innovation, cost effectiveness, speed/throughput, technology advancement, ease-of-use, quality, and maintainability.

The FlexVIA Plasma System is used during PCB manufacture to uniformly treat the inner surface layer of flex PCBs prior to lamination for improved adhesion and reliability. The system features a space-saving, compact chassis and an advanced horizontal electrode design to provide optimum material alignment. Utilizing patented plasma technology, the FlexVIA System does not require the use of temperature control, a blower, or expensive fluorine gases. Environmentally friendly and cost-effective gas plasma solutions, such as argon (Ar) and oxygen (O2), are utilized to maximize cost savings. The dual-rack chamber accommodates up to eighteen 20 x 24 inch panels in a single cycle and both sides of the flex material surface area are treated in a single-step process enabling a rate of 80 to 120 units per hour (UPH).

“We would like to thank EM Asia-China and its panel of industry experts for this recognition,” stated Dr. James Getty, president, Nordson MARCH. “The FlexVIA System represents significant advances in plasma treatment technology that is based upon the innovations and expertise we have developed during more than 25 years in this field.”

Photo available at: http://www.nordson.com/en-us/divisions/march/PublishingImages/High-Res/NordsonMARCH-EMAsia-China-2013-cropped.jpg

Caption: Rocky Yin, East/North China Sales Manager (left), and Leo Li, China General Manager (middle), of Nordson MARCH accept EM Asia award.

About Nordson MARCH

Nordson MARCH is the global leader in plasma processing technology for the semiconductor, printed circuit board (PCB), microelectronics, and medical & life science device manufacturing industries. Nordson MARCH has offices and applications laboratories worldwide, including California, Florida, Europe, Singapore, China, Japan, Korea and Taiwan. With over 25 years of continuous innovation, Nordson MARCH designs and manufactures a complete line of award-winning and patented plasma processing systems. An expert staff of scientists and engineers is available to assist in the development of plasma processes that improve product reliability and increase production yields. Visit Nordson MARCH on the web at www.nordsonmarch.com, or social media Facebook, Google+, LinkedIn, or YouTube.

About Nordson Corporation

Nordson Corporation (NASDAQ: NDSN) is one of the world’s leading producers of precision dispensing equipment that applies adhesives, sealants, liquid and powder coatings and other materials to a broad range of consumer and industrial products during manufacturing operations. The company also manufactures equipment used in the testing and inspection of electronic components as well as technology-based systems for UV curing and surface treatment processes. Headquartered in Westlake, Ohio, Nordson has direct operations and sales support offices in more than 30 countries. Visit Nordson on the web at www.nordson.comwww.twitter.com/Nordson_Corp or Facebook.

CONTACT

Nordson MARCH (International Headquarters)
Roberta Foster-Smith
+1-925-827-1240
Roberta.foster-smith@nordsonmarch.com
http://www.nordsonmarch.com
or
Agency
Contact:
A R Marketing, Inc.
Andrea Roberts
+1-858-451-8666
andrea@armarketinginc.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)